The RECOVERY Trial – two years on.

The RECOVERY Trial – two years on – University of Oxford

Related:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

Commentary on Twitter

https://twitter.com/MartinLandray/status/1508492188560371717